Artiva Biotherapeutics Reports Two Grade 5 Events, One Likely Linked to Fludarabine Toxicity
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Universal Music Group Reports Third-Quarter and Nine-Month Results
M impact | EQUITY | Oct 29, 2026, 04:54 PM UTC
UMG Q3 Recorded Music Subscription Revenue Grew 19.2%
Revenue growth was 9.5% excluding Downtown.
M impact | EQUITY | Oct 29, 2026, 04:47 PM UTC
AXA Reports 5% Rise in Nine-Month Life and Health Premiums
AXA reported a 5% increase in premiums over nine months, driven by life and health insurance.
M impact | EQUITY | Oct 29, 2026, 04:47 PM UTC
AXA Reports 9-Month Gross Written Premiums and Other Revenues of €93.0 Billion
M impact | EQUITY | Oct 29, 2026, 04:46 PM UTC
Eutelsat to Gain Access to More Than Twice Current OneWeb Capacity
The added capacity is expected to support estimated service revenue of more than €10 billion over 2032–2040.
M impact | EQUITY | Oct 29, 2026, 04:46 PM UTC
Median Technologies Reports Q3 iCRO Revenue of €6.7M, Backlog of €90.9M
Q3 2026 iCRO revenue rose 14.4% year over year. The company reported a record order backlog of €90.9M and cash of €58.3M at September 30, 2026. Year-to-date revenue was €18.5M, ver
M impact | EQUITY | Oct 29, 2026, 04:45 PM UTC